---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-060085"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T03:58:38.405286+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Q1: $36.7M Attruby revenue, net loss $167.4M, pipeline advances

## Summary
- First full quarter of Attruby net product revenue $36.7M; 2,072 prescriptions from 756 prescribers since Nov 2024 FDA approval.
- Net loss attributable to common stockholders $167.4M ($0.88 EPS) vs $35.2M ($0.20) YoY; total revenue $116.6M vs $211.1M.
- Cash $540.6M at March 31, 2025; expects $105M milestone payments in Q2 for ex-U.S. BEYONTTRA approvals.
- Phase 2 encaleret in hypoparathyroidism: 78% of 9 patients achieved normal blood & urine calcium within 5 days.
- Priced $500M 1.75% convertible notes due 2031; used $459M to repay term loan; Thomas Trimarchi appointed President/CFO.

## SEC filing metadata
- accession: 0000950170-25-060085
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000095017025060085/0000950170-25-060085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000095017025060085/bbio-20250429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-060085
- JSON: https://secwatch.observer/filing/0000950170-25-060085.json
- Plain text: https://secwatch.observer/filing/0000950170-25-060085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.